IDH1 and cholangiocarcinoma: In the present study, we identified IDH1 and IDH2 mutations in 3.1% (six of 195) of patients with CC; hence, the incidence of IDH mutations in our cohort was relatively low, compared to the incidences in previous reports (5–7, 9, 17).